论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
PIM-1激酶:三阴性乳腺癌的潜在生物标志物
Authors Chen J, Tang G
Received 18 April 2019
Accepted for publication 30 July 2019
Published 8 August 2019 Volume 2019:12 Pages 6267—6273
DOI https://doi.org/10.2147/OTT.S212752
Checked for plagiarism Yes
Review by Single-blind
Peer reviewers approved by Dr Shashank Kaushik (PT)
Peer reviewer comments 2
Editor who approved publication: Dr Sanjeev Srivastava
Abstract: Triple-negative breast cancer is associated with a poor prognosis, and effective biomarkers for targeted diagnosis and treatment are lacking. The tumorigenicity of the provirus integration site for Moloney murine leukemia virus 1 (PIM-1 ) gene has been studied for many years. However, its significance in breast cancer remains unclear. In this review we briefly summarized the physiological characteristics and regulation of PIM-1 kinase, and subsequently focused on the role of PIM-1 in tumors, especially breast cancer. Oncogene PIM-1 was found to be upregulated in breast cancer, especially in triple-negative breast cancer. Moreover, it is involved in tumorigenesis and the development of drug resistance, and linked to poor prognosis. A highly selective probe targeting PIM-1 for imaging has emerged, suggesting that PIM-1 may be a potential biomarker for the accurate diagnosis and targeted therapy of triple-negative breast cancer.
Keywords: triple-negative breast cancer, biomarker, PIM-1